RT Journal Article SR Electronic T1 Comment on “Drug Screening for ALS Using Patient-Specific Induced Pluripotent Stem Cells” JF Science Translational Medicine FD American Association for the Advancement of Science SP 188le2 OP 188le2 DO 10.1126/scitranslmed.3005065 VO 5 IS 188 A1 Bilican, Bilada A1 Serio, Andrea A1 Barmada, Sami J. A1 Nishimura, Agnes Lumi A1 Sullivan, Gareth J. A1 Carrasco, Monica A1 Phatnani, Hemali P. A1 Puddifoot, Clare A. A1 Story, David A1 Fletcher, Judy A1 Park, In-Hyun A1 Friedman, Brad A. A1 Daley, George Q. A1 Wyllie, David J. A. A1 Hardingham, Giles E. A1 Wilmut, Ian A1 Finkbeiner, Steven A1 Maniatis, Tom A1 Shaw, Christopher E. A1 Chandran, Siddharthan YR 2013 UL http://stm.sciencemag.org/content/5/188/188le2.abstract AB Egawa et al. recently showed the value of patient-specific induced pluripotent stem cells (iPSCs) for modeling amyotrophic lateral sclerosis in vitro. Their study and our work highlight the need for complementary assays to detect small, but potentially important, phenotypic differences between control iPSC lines and those carrying disease mutations.